Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 2531-2531 ◽  
Author(s):  
T. Evans ◽  
C. R. Lindsay ◽  
E. Chan ◽  
B. Tait ◽  
S. A. Michael ◽  
...  
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Phase I ◽  
Insulin Receptor ◽  
Tyrosine Kinase Inhibitor ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Kinase Inhibitor ◽  
Advanced Solid Tumors ◽  
Dose Escalation Study

Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 2540-2540 ◽  
Author(s):  
D. S. Hong ◽  
B. S. Koetz ◽  
R. Kurzrock ◽  
N. N. Senzer ◽  
W. Hanekom ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Phase I ◽  
Tyrosine Kinase Inhibitor ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Kinase Inhibitor ◽  
Dose Escalation Study
Sign in / Sign up

Export Citation Format

Share Document